E-mail
Àλ縻
ÀÓ¿øÁø
¿¬Çõ
´ë±¹¹ÎȰµ¿
ºÐ°úÇÐȸ
¼Ò½ÄÁö
ÀÇ·á°èµ¿Á¤
ÇÐȸµ¿Á¤
Àλ絿Á¤
ÀÌ´ÞÀÇÀÎÅͺä
È­º¸
Áö³­È£º¸±â
Home > ÇÐȸ¼Ò°³ > ¼Ò½ÄÁö > ÇÐȸ µ¿Á¤
2013³â ´ëÇѹé½ÅÇÐȸ Ãá°èÇмú´ëȸ 2013.03.18
ÀÛ¼ºÀÚ    °ü¸®ÀÚ Á¶È¸¼ö    1384

¾È³çÇϽʴϱî?

µ¹¾Æ¿À´Â 2013³â º½À» ¸Â¾Æ, ´ëÇѹé½ÅÇÐȸÀÌ 3¹øÂ° Çмú´ëȸ·Î Ãá°ÔÇмú´ëȸ¸¦ °³ÃÖÇÕ´Ï´Ù. Áö³­ Ãá°è, Ãß°èÇмú´ëȸµµ ¿©·¯ ȸ¿ø´Ôµé²²¼­ Àû±ØÀûÀ¸·Î Âü¿©ÇØÁֽðí, ½ÉÆ÷Áö¾ö ÁÖÁ¦¿Í ¹ßÇ¥ ³»¿ë¿¡ ´ëÇØ¼­µµ ¾ÆÁÖ ±àÁ¤ÀûÀ¸·Î Æò°¡ÇØ Áּż­ ¸¹Àº ÈûÀÌ µÇ¾ú½À´Ï´Ù.

CEVR 2
¹øÂ° ¹ßÇົÀÌ 1¿ù¿¡ ÀμâµÇ¾ú°í, ¿©·¯ ȸ¿ø´Ôµé²² Àü´ÞµÇ¾úÀ» ÁÙ ¾Ð´Ï´Ù. ¿Ã ÇØ´Â ´ëÇѹé½ÅÇÐȸ°¡ ±¹³» ¿©·¯ ¹é½Å°ü·Ã Àü¹®°¡µé¿¡°Ô Á» ´õ Ä£¼÷ÇÑ ¸ðÀÓÀ¸·Î ´Ù°¡°¡°í, ±Û·Î¹úÇÑ ³×Æ®¿öÅ©¸¦ ¸¸µé¾î°¡´Â ½Ã°£ÀÌ µÉ ¼ö ÀÖµµ·Ï ÇϰڽÀ´Ï´Ù.

À̹ø Ãá°èÇмú´ëȸ¿¡¼­´Â ½ÉÆ÷Áö¾ö ³× °¡ÁöÀÇ ÁÖÁ¦¿Í Ưº° °­¿¬À» ¸¶·ÃÇÏ¿´½À´Ï´Ù.
Àμö°øÅë°¨¿°º´ÀÇ ¼Ò°³¿Í ¹é½Å»ç¿ë, ¹é½ÅÀÇ °³¹ß Áß ¹é½ÅÀÇ Á¢Á¾¹ý¿¡ °üÇÑ ¿¬±¸¿Í ÀÓ»óÀû¿ë, ±×¸®°í »ç¶÷ ¹é½ÅÀÇ ÃÖ±Ù °¡ÀÌµå º¯È­¿Í °³¹ß ÇöȲÀ» ¼Ò°³Çϰí, ºñ°¨¿°¼º ¹é½ÅÀ¸·Î ¾Ï¹é½ÅÀÇ °³¹ß¿¡ °üÇÑ ÃֽŠÁö°ßÀ» Á¢ÇÏ½Ç ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, Ưº° °­¿¬À» ÅëÇØ µ¿°æ´ë Kiyono Hiroshi¹Ú»ç¸¦ ÃÊûÇÏ¿© Á¡¸·¸é¿ª¿¡ °üÇÑ ¼¼°èÀûÀÎ È帧À» ´À³¢½Ç ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.

±â²¨ÀÌ Æ¯º° °­¿¬À» ¸Ã¾ÆÁֽŠKiyono Hiroshi ±³¼ö´Ô°ú ½ÉÆ÷Áö¾ö ¹ßÇ¥ÀÚ·Î Âü¿©ÇØÁÖ½Ç ¿©·¯ ¼±»ý´Ôµé²² Áø½ÉÀ¸·Î °¨»ç¸¦ µå¸³´Ï´Ù.

À̹ø Çмú´ëȸ°¡ ȸ¿ø ¿©·¯ºÐµéÀÇ Àû±ØÀûÀÎ Âü¿©¿Í ÇÔ²² Ȱ¹ßÇÑ Åä·ÐÀÇ ÀåÀÌ µÇ¸®¶ó È®½ÅÇÕ´Ï´Ù.

°¨»çÇÕ´Ï´Ù.

´ëÇѹé½ÅÇÐȸ
ȸÀå ±è Á¤ ¼ö ¿Ã¸²

09:00

°³È¸»ç

±èÁ¤¼ö ȸÀå

9:00-10:30

Session I ; Vaccine for Zoonosis

ÁÂÀå:

 ÀÌÁߺ¹(°Ç±¹´ë)
 
À¯ÇÑ»ó(¼­¿ï´ë)

 

Characteristics of hepatitis E virus and development of the vaccine

ÃÖÀμö(°Ç±¹´ë)

 

»ì¸ð³Ú¶ó¹é½Å °³¹ßÇöȲ ¹× Àü¸Á

ÀÌÈñ¼ö
(
³ó¸²¼ö»ê°Ë¿ªº»ºÎ)

 

Zoonotic and vector-borne viral diseases: transmission and epidemiology

°íÀ±¿µ
(
Çѱ¹È­Çבּ¸¿ø)

10:30-10:40

Coffee break

 

10:40-12:10

Session II ; Vaccine delivery; Bench to bedside

ÁÂÀå:

 ÀÌÁØÇà(Àü³²´ë)
 
¼º¹é¸°(¿¬¼¼´ë)

 

Microneedle patches for improved influenza vaccination

±èÀ¯Ãµ(Ä«À̽ºÆ®)

 

Eye-drop vaccination induce systemic and mucosal immune response against influenza virus

¼­°æ·ü(¿¬¼¼´ë)

 

papillomavirus-associated diseases: progresses in clinical and animal studies

½ÅÁ¤ÀÓ(°­¿ø´ë)

12:10-13:10

·±Ãµ½ÉÆ÷Áö¿ò

 

13:10-13:50

Invited lecture

ÁÂÀå:

 ±èÁ¤¼ö(ÀüºÏ´ë)

 

Forward Motion in the Development of Ideal Mucosal Vaccine

Kiyono Hiroshi
(
µ¿°æ´ë)

 

13:50-15:20

Session III ; Human vaccines

ÁÂÀå:

 °­ÁøÇÑ(°¡Å縯´ë)
 
¿À¸íµ·(¼­¿ï´ë)

 

Changes in PPV guidelines

Á¤ÈñÁø(°í·Á´ë)

 

Vaccine storage and management

ÀÌÅÃÁø(ºÐ´çÂ÷º´¿ø)

 

Tuberculosis vaccine

·ù¼º¿ø(°áÇÙ¿¬±¸¿ø)

15:20-15:30

Coffee break

 

15:30-17:00

Session IV ; Immune cell-based Therapeutic Cancer Vaccine

ÁÂÀå:

 ¹è¿ë¼ö(¼º±Õ°ü´ë)
 
±èâÈÖ
(
¼øÃµÇâÀÇ´ë)

 

Dendritic cell therapy against multiple myeloma

ÀÌÁ¦Áß (Àü³²´ë)

 

Core-shell nanoparticles for anti-cancer DC immunotherapy

¼º½Â¿ë (¼­¿ï´ë)

 

Strategies to enhance CEA specific antitumor immunity in murine model

±èÅÂ±Ô (°¡Å縯´ë)

17:00

Æóȸ»ç

±èÁ¤¼ö ȸÀå

»çÀüµî·Ï ±â°£: 2013³â 2¿ù 28ÀÏ(±Ý)

 (Á¢¼ö ¸¶°¨ÀÏ ÀÚÁ¤ÀÌ Áö³ª¸é ÀÎÅÍ³Ý Á¢¼ö âÀº ȨÆäÀÌÁö¿¡¼­ Æó¼âµÇ¿À´Ï Á¢¼ö ¸¶°¨ ÀÏÀ» ²À ÁöÄÑÁֽʽÿÀ.)

 

»çÀüµî·Ï ¹æ¹ý

¡æ

ÇÐȸ ȨÆäÀÌÁöÀÇ ÇмúÇà»ç ÆäÀÌÁö '»çÀüµî·Ï' ¸Þ´º¸¦ ¸¶¿ì½º·Î Ŭ¸¯ÇÕ´Ï´Ù.

¡æ

»çÀüµî·Ï ÀÛ¼º¿ä·É¿¡ µû¶ó ÀÔ·ÂÇÏ¿© »çÀüµî·Ï ½ÅûÀÌ Á¢¼ö µÇ¸é µî·ÏÈ®ÀÎ À̸ÞÀÏÀ» º¸³»µå¸®¸ç, ÇÐȸ¿¡¼­ µî·Ïºñ ÀÔ±Ý ¿©ºÎ¸¦ È®ÀÎ ÀÌ»óÀÌ ¾øÀ» °æ¿ì ÀÔ±Ý È®ÀÎ À̸ÞÀÏÀ» ¹ß¼ÛÇÕ´Ï´Ù.

¡æ

»çÀüµî·Ï ½Ã ÀÎÅÍ³Ý »çÀüµî·Ï¸¸ ÇϽðí, µî·Ïºñ ¼Û±ÝÀ» ÇÏÁö ¾ÊÀ» °æ¿ì¿Í µî·Ïºñ¸¸ ¼Û±ÝÇϰí ÀÎÅÍ³Ý »çÀüµî·ÏÀ» ÇÏÁö ¾ÊÀ» °æ¿ì »çÀüµî·ÏÀÌ µÇÁö ¾Ê½À´Ï´Ù. ¹Ýµå½Ã ¿Â¶óÀÎ »çÀüµî·Ï ½Åû ¹× µî·Ïºñ ÀÔ±ÝÀ» ¸ðµÎ ÇÏ¼Å¾ß ÇÕ´Ï´Ù.

¡æ

µî·Ïºñ °áÀç ¹æ¹ý : ½Å¿ëÄ«µå ¹× ¿Â¶óÀÎÀԱݽà ¹Þ½À´Ï´Ù. ¿Â¶óÀÎÀԱݽà ¼Û±ÝÀÎÀ» Á¤È®È÷ Àû¾îÁֽʽÿÀ.

*

»çÀüµî·Ï¸¶°¨ÀÌÈÄ(2¿ù 28ÀÏ) ȯºÒÀÌ ºÒ°¡ÇÕ´Ï´Ù.(Çà»ç´çÀÏ ¹× Çà»ç Á¾·á ÈÄ È¯ºÒ ºÒ°¡)

 

»çÀüµî·Ï

±¸ ºÐ

±¸ ºÐ

»çÀüµî·Ïºñ

ȸ¿ø

Àü°øÀÇ, ´ëÇÐ, ´ëÇпø ÀçÇлý, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø

2¸¸¿ø

ÀüÀÓÀÇ, ¹Ú»ç±Þ ÀÌ»ó ¼±ÀÓ ¹× Ã¥ÀÓ ¿¬±¸ÀÚ

3¸¸¿ø

ºñȸ¿ø

 ºñȸ¿ø

5¸¸¿ø

 

ÇöÀåµî·Ï

±¸ ºÐ

±¸ ºÐ

ÇöÀåµî·Ïºñ

ȸ¿ø

Àü°øÀÇ, ´ëÇÐ, ´ëÇпø ÀçÇлý, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø

4¸¸¿ø

ÀüÀÓÀÇ, ¹Ú»ç±Þ ÀÌ»ó ¼±ÀÓ ¹× Ã¥ÀÓ ¿¬±¸ÀÚ

5¸¸¿ø

ºñȸ¿ø

 ºñȸ¿ø

7¸¸¿ø

1363595589_1361164689_¹é½ÅÆ÷½ºÅÍ.pdf1363595589_1361164689_¹é½ÅÆ÷½ºÅÍ.pdf


Àüü °Ô½Ã¹°À» º¾´Ï´Ù.